Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and CAMBRIDGE, Mass., April 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
April 07, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
March 08, 2022 16:35 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 28, 2022 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 15, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began...
February 09, 2022 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 02, 2022 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative...
November 23, 2021 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 22, 2021 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 16, 2021 08:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

-Initiation of patient enrollment expected by year-end- ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a...